Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AbbVie Inc (ABBV) vs Riot Platforms Inc (RIOT) Price & Performance

AbbVie IncTrade
Riot Platforms IncTrade

Price performance (Past 24H)

Key statistics

AbbVie Inc vs Riot Platforms Inc — how do they compare? AbbVie Inc trades at $249.1 (market cap $441.94B), while Riot Platforms Inc trades at $20.29 (market cap $7.59B). The key difference: AbbVie Inc is far larger — about 58.2× Riot Platforms Inc's market cap, and AbbVie Inc pays a 2.77% dividend while Riot Platforms Inc pays none. Which is the better fit depends on your goals.

ABBVRIOT
Market Cap
$441.94B$7.59B
Sector
HealthTechnology
52-Week High
$263.58$28.67
52-Week Low
$197.38$11.33
Enterprise Value
$506.19B$8.00B
Dividend Yield
2.77%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AbbVie Inc

AbbVie (ABBV) trades at $248.40, up 0.2% with a bullish technical signal supported by moving averages. The company demonstrates strong revenue growth to $61.16B in 2025 and consistent earnings beats, though net margins have compressed. Recent positive Phase 2 data for ELAHERE in ovarian cancer and institutional buying activity highlight ongoing momentum. Valuation ratios appear elevated with a P/E of 70.65 and P/B of 245.29, reflecting premium pricing for its pharmaceutical pipeline.

Outlook remains positive with 70.7% analyst buy ratings and a $278.69 consensus target offering 12% upside. Key risks include patent expirations, regulatory challenges from drug pricing lawsuits, and high debt levels. The dividend aristocrat status and robust immunology portfolio position ABBV for sustained growth, though investors should monitor execution against lofty 2026 EPS expectations of $3.87 for Q3.

Riot Platforms Inc

RIOT Platforms trades at $20.835, up 7.4% on news of a transformative $9.1 billion AI infrastructure deal with Anthropic. Despite bearish technical signals and consecutive quarterly losses, the stock shows strong momentum driven by the company's strategic pivot from bitcoin mining to data center operations. Analyst sentiment remains overwhelmingly positive with 94% buy ratings and a $33.40 consensus price target, representing significant upside potential.

The outlook hinges on successful execution of the AI infrastructure strategy, though substantial risks persist including negative cash flow, widening losses, and competitive pressures. Investors face a high-risk, high-reward scenario where the massive Anthropic deal could drive long-term value if operational challenges are overcome.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AbbVie Inc

AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.

Read more on ABBV

About Riot Platforms Inc

Riot Platforms, Inc. is a Bitcoin mining company that focuses on building, operating, and expanding large-scale infrastructure for digital asset mining in North America. The company's operations include Bitcoin mining, data center hosting, and engineering solutions. Riot's strategy emphasizes vertical integration to maximize efficiency and scale its mining capacity, aiming to be a leader in the global Bitcoin and digital infrastructure industry.

Read more on RIOT